ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

9:45AM-10:00AM: Abstract Number: 0772

Redefining When to Biopsy the Kidney in Patients with SLE

Plenary I (0772–0776)

10:00AM-10:15AM: Abstract Number: 0773

Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis

Plenary I (0772–0776)

10:15AM-10:30AM: Abstract Number: 0774

Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion

Plenary I (0772–0776)

10:30AM-12:30PM: Abstract Number: 0317

“No matter how great my doctor is, he hasn’t had a knee replacement, he doesn’t understand all that pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement

(0306–0336) Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0189

“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists

(0175–0198) Health Services Research Poster I

10:30AM-12:30PM: Abstract Number: 0359

“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0446

A Balancing Act: The Interplay Between Resilience and Frailty in Rheumatoid Arthritis

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0613

A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0719

A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis

(0711–0730) Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0309

A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative

(0306–0336) Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0041

A genetically determined, serine-based and phosphorylation-dependent molecular switch regulates the inflammatory potential of human IgA

(0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0182

A Joint Effort: Implementing Depression Screening in a Safety-Net Rheumatology Clinic

(0175–0198) Health Services Research Poster I

10:30AM-12:30PM: Abstract Number: 0467

A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0519

A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study

(0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

10:30AM-12:30PM: Abstract Number: 0263

A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

1
2
3
…
57
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].